Evolocumab is a monoclonal antibodies against the PCSK9 enzyme (PCSK9 inhibitors). PCSK9 is synthesized and secreted by hepatocytes and binds to LDLR (low‐density lipoprotein receptor) on the surface of hepatocytes. LDLR promotes internalization and degradation, is an effective target for prevention of cardiovascular diseases. The reduction of surface LDLR can effectively reduce the uptake of LDL (low‐density lipoprotein) and increase the concentration of LDL-C (cholesterol) in the blood, which can lead to cardiovascular disease (CVD). Evolocumab binds to PCSK9 enzyme with high affinity, disrupting its ability to bind to LDLR. By inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme, the antibody can reduce LDL‐C and CVD risk.
